Department of Oncology and Metabolism, Medical School, The University of Sheffield, Sheffield, UK.
Department of Oncology and Metabolism, Medical School, The University of Sheffield, Sheffield, UK; Biomolecular Research Centre, Sheffield Hallam University, Sheffield, UK.
Life Sci. 2021 Mar 15;269:119040. doi: 10.1016/j.lfs.2021.119040. Epub 2021 Jan 13.
Low testosterone in men is associated with increased cardiovascular events and mortality. Testosterone has beneficial effects on several cardiovascular risk factors including cholesterol, endothelial dysfunction and inflammation as key mediators of atherosclerosis. Although evidence suggests testosterone is anti-atherogenic, its mechanism of action is unknown. The present study investigates whether testosterone exerts anti-atherogenic effects by stimulating cholesterol clearance from macrophages via activation of liver X receptor (LXRα), a nuclear master regulator of cellular cholesterol homeostasis, lipid regulation, and inflammation.
Using human monocyte THP-1 cells differentiated into macrophages, the effect of testosterone (1-10 nM) treatment (24-72 h) on the expression of LXRα and LXR- targets apolipoprotein E (APOE), ATP-binding cassette transporter A1 (ABCA1), sterol regulatory element-binding transcription factor 1 (SREBF1) and fatty acid synthase (FAS), was investigated via qPCR and western blotting, with or without androgen receptor blockade with flutamide or LXR antagonism with CPPSS-50. Cholesterol clearance was measured by monitoring fluorescent dehydroergosterol (DHE) cellular clearance and ABCA1 cellular translocation was observed via immunocytochemistry in testosterone treated macrophages.
Testosterone increased mRNA and protein expression of LXRα, APOE, ABCA1, SREBF1 and FAS. These effects were blocked by flutamide and independently by LXR antagonism with CPPSS-50. Furthermore testosterone stimulated cholesterol clearance from the macrophages and promoted the translocation of ABCA1 toward the cell membrane.
Testosterone acts via androgen receptor-dependent pathways to stimulate LXRα and downstream targets to induce cholesterol clearance in human macrophages. This may, in part, explain the anti-atherogenic effects of testosterone frequently seen clinically.
男性的睾丸激素水平降低与心血管事件和死亡率的增加有关。睾丸激素对多种心血管风险因素有有益影响,包括胆固醇、内皮功能障碍和炎症,这些都是动脉粥样硬化的关键介质。尽管有证据表明睾丸激素具有抗动脉粥样硬化作用,但它的作用机制尚不清楚。本研究旨在通过激活肝脏 X 受体(LXRα)来研究睾丸激素是否通过刺激巨噬细胞清除胆固醇来发挥抗动脉粥样硬化作用,LXRα 是细胞胆固醇稳态、脂质调节和炎症的核主调控因子。
使用人类单核细胞 THP-1 细胞分化为巨噬细胞,通过 qPCR 和 Western blot 检测睾丸激素(1-10 nM)治疗(24-72 小时)对 LXRα 和 LXR 靶标载脂蛋白 E(APOE)、三磷酸腺苷结合盒转运蛋白 A1(ABCA1)、固醇调节元件结合转录因子 1(SREBF1)和脂肪酸合酶(FAS)的表达的影响,同时用氟他胺阻断雄激素受体或 CPPSS-50 阻断 LXR 拮抗作用。通过监测荧光去氢麦角固醇(DHE)细胞清除率来测量胆固醇清除率,并通过免疫细胞化学观察睾丸激素处理的巨噬细胞中 ABCA1 细胞易位。
睾丸激素增加了 LXRα、APOE、ABCA1、SREBF1 和 FAS 的 mRNA 和蛋白表达。这些作用被氟他胺阻断,并且可以被 CPPSS-50 独立阻断。此外,睾丸激素刺激巨噬细胞中的胆固醇清除,并促进 ABCA1 向细胞膜的易位。
睾丸激素通过雄激素受体依赖性途径作用,刺激 LXRα 和下游靶标,在人类巨噬细胞中诱导胆固醇清除。这可以部分解释临床上经常观察到的睾丸激素的抗动脉粥样硬化作用。